跳至主要内容

Factors Affecting Drug Metabolism

 Drug metabolism refers to the chemical change process of drugs in the body. Most drugs lose their activity after being metabolized, and are converted into extremely high water-soluble metabolites, which are beneficial to excretion from the body. There are also some drugs that are hardly metabolized in the body and are excreted as original drugs. For more details, please read Factors Affecting Pharmacokinetics of Drugs.

The metabolism of drugs requires the participation of enzymes. The liver is an important organ for drug metabolism. The cytochrome P-450 enzyme system of liver microsomes is the main enzyme system that promotes drug metabolism, so it is called liver drug enzymes. Some drugs can also be decomposed by related enzymes in other tissues.

The availability and content of liver drug enzymes are not unstable, and individual differences are large, and they are easily affected by certain drugs. Any drug that can enhance the activity of liver drug enzymes or accelerate the synthesis is called drug enzyme inducer, which can accelerate the metabolism of the drug itself and some other drugs, which is one of the reasons for drug tolerance. For example, phenobarbital has a strong drug-enzyme induction effect, and continuous medication can accelerate its own metabolism and that of the anticoagulant warfarin, reducing its efficacy. Any drug that can reduce the activity or synthesis of drug enzymes is called drug enzyme preparations, which can slow down the metabolism of some other drugs and enhance the drug effect. For example, chloramphenicol is a drug enzyme inhibitor, which can slow down the metabolism of phenytoin sodium. Taking the two drugs together can increase the blood concentration of phenytoin sodium, enhance the efficacy, and even cause toxic reactions. Therefore, it is necessary to pay attention to the mutual influence of the drugs when combining drugs.

Contact Us 

Email : marketing@medicilon.com

Tel : +44 1223 981 792（Europe）

        +82 (0)70-8269-5849（South Korea）

        08044216898（Japan）

        +86 021 58591500（China )

Website: https://www.medicilon.com

Related Articles:

Factors Affecting Pharmacokinetics of Drugs

Factors Affecting Metabolism

标签：

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文